title: Thromboxane metabolite excretion in patients with hand-arm vibration syndrome.
abstract: As chronic exposure to hand-held vibrating tools may cause endothelial injury, a subsequent sustained platelet activation with the increased release of vasoconstricting thromboxane A2 (TxA2) could be of pathophysiological importance in vibration-induced Raynaud's phenomenon. Therefore, the aim of this study was to elucidate whether or not hand-arm vibration syndrome is accompanied by increased endogenous TxA2 biosynthesis. The study involved 64 men, aged 23-61 years, stratified according to the exposure to vibrating tools, the presence of Raynaud's phenomenon, and smoking habit. Forty of them were car mechanics and 24 were age-matched healthy volunteers who served as controls. The assessment of platelet TxA2 formation in vivo was performed by quantification of the urinary excretion of its major metabolite, 2,3-dinorthromboxane B2 (2,3-dinor-TxB2), employing gas chromatography-mass spectrometry. The average urinary excretion rate of 2,3-dinor-TxB2 in patients with Raynaud's phenomenon was 296 +/- 42 pg/mg creatinine and did not differ significantly from the corresponding values in controls (328 +/- 62 pg/mg creatinine) or individuals exposed to vibrating tools, but without any signs of vasospastic disease (232 +/- 29 pg/mg creatinine). The only statistically significant difference was found between smokers and non-smokers (P < 0.001), a finding confirming the existence of chronic platelet dysfunction in cigarette smokers. The present data indicate that chronic exposure to vibrating tools, with or without Raynaud's phenomenon, is not associated with an enhanced platelet function as monitored by the urinary excretion of 2,3-dinor-TxB2. Hence, a possible vibration-induced vascular injury does not seem to provide a stimulus sufficient to induce a persistent platelet activation.
authors.affiliation: Department of Clinical Physiology, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Nowak
authors.forename: L
authors.initials: L
authors.lastname: Barregård
authors.forename: G
authors.initials: G
authors.lastname: Benthin
authors.forename: G
authors.initials: G
authors.lastname: Granung
authors.forename: A
authors.initials: A
authors.lastname: Wennmalm
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000502:physiology*; D002849:Chromatography, Gas; D002853:Chromatography, Liquid; D003404:Creatinine / Q000652:urine; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D011928:Raynaud Disease / Q000209:etiology / Q000503:physiopathology / Q000652:urine*; D013577:Syndrome; D013928:Thromboxane A2 / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine; D014661:Vasoconstriction; D014732:Vibration / Q000009:adverse effects*
chemical_list: D013929:Thromboxane B2; D013928:Thromboxane A2; C028965:2,3-dinor-thromboxane B2; D003404:Creatinine